Medtronic Lands FDA Clearance for Stealth AXiS Spine Robot Days Before FQ3 Earnings, Signaling a New Platform Era

Medtronic received FDA clearance for its Stealth AXiS surgical system — the first integrated planning, navigation, and robotics platform for spine surgery — on the same day Needham upgraded the stock to Buy with a $121 target. With FQ3 2026 earnings dropping February 17, the $129B medtech giant is stacking catalysts: the CathWorks acquisition, a planned diabetes spinoff, 71% growth in cardiac ablation, and Elliott Management at the boardroom table.

MDT · Health Care · February 13, 2026

S&P 500 Position

Within Health Care Equipment, Medtronic sits behind Abbott ($220B+), Intuitive Surgical (~$190B), and Stryker (~$140B), and ahead of Edwards Lifesciences and Becton Dickinson. Medtronic held the title of world's largest medtech company by revenue for years, but Johnson & Johnson MedTech is positioned to overtake it after the MiniMed spinoff reduces Medtronic's top line by ~$2.8B. Boston Scientific and Stryker have outperformed on growth and multiples, pushing Medtronic into value territory among its peers.

Index Weight: ~0.25% | Rank: Approximately #80-90 in the S&P 500 by market cap

Company Overview

Medtronic is executing a portfolio-level transformation under pressure from activist investor Elliott Management, reshaping itself from a sprawling medical device conglomerate into a more focused, higher-margin medtech platform company. The centerpiece of today's news cycle is the FDA clearance of Stealth AXiS, a next-generation surgical robotics platform that integrates preoperative planning, real-time navigation, and robotic execution into a single system for spine surgery. This is the successor to the Mazor robotics line Medtronic acquired in 2018, and it slots into the broader AiBLE ecosystem — a connected surgical intelligence layer that links imaging, AI-driven planning, and intraoperative data across the continuum of care. The architecture is modular and designed to expand into cranial and ENT procedures pending further 510(k) clearance. The company's growth narrative has shifted decisively toward its Cardiovascular segment, where Pulsed Field Ablation (PFA) products delivered 71% organic growth in FQ2 2026 via the Affera and Sphere-9 catheter families. Meanwhile, Medtronic announced in May 2025 that it will spin off its $2.8B Diabetes business as MiniMed, an independent publicly traded entity — a move designed to shed a lower-margin, consumer-oriented unit and refocus the remaining ~$31B business on high-margin medtech categories. The spinoff IPO filing dropped in December 2025 and the separation is expected to complete by end of calendar year 2026. With the pending $585M CathWorks acquisition adding AI-powered coronary diagnostics and the Hugo soft-tissue robotics platform progressing through trials, Medtronic is stacking a dense product roadmap across multiple billion-dollar markets.

Products & Revenue

Medtronic generates revenue across four operating segments, with Cardiovascular as the largest and fastest-growing franchise. The PFA catheter portfolio (Cardiac Ablation Solutions) crossed $1B in annual revenue in FY2025, growing nearly 50% in Q1 FY2026 alone. Neuroscience is the second-largest segment, anchored by Cranial & Spinal Technologies (including the newly cleared Stealth AXiS system) and the high-margin Neuromodulation business. Medical Surgical includes the Hugo robotics platform and the GI Genius AI endoscopy module. The Diabetes segment, slated for spinoff as MiniMed, generates roughly 8% of total revenue but only ~4% of operating profit, making it a margin drag the company is actively shedding.

Cardiovascular (37%): Cardiac Rhythm & Heart Failure (pacemakers, defibrillators, CRT), Structural Heart & Aortic (TAVR valves, stent grafts), Coronary & Peripheral Vascular (stents, balloons, renal denervation), and Cardiac Ablation Solutions (PFA catheters, Affera mapping). The fastest-growing segment at +9.3% in Q1 FY2026.

Neuroscience (29%): Cranial & Spinal Technologies (Stealth AXiS, Mazor robotics, AiBLE ecosystem, implants), Specialty Therapies (ENT, pelvic health), and Neuromodulation (spinal cord stimulation, deep brain stimulation). Grew 4.3% in Q1 FY2026.

Medical Surgical (25%): Surgical & Endoscopy (Hugo RAS platform, LigaSure vessel sealing, GI Genius AI endoscopy, Touch Surgery Enterprise) and Acute Care & Monitoring (patient monitoring, airway management). The flattest segment at ~1% growth.

Diabetes (8%): MiniMed 780G automated insulin delivery system, Simplera Sync and Instinct CGM sensors, InPen smart insulin pen. Being spun off as standalone MiniMed entity via IPO + split-off by end of CY2026.

Based on FY2025 10-K (fiscal year ended April 25, 2025): Cardiovascular $12.5B, Neuroscience $9.8B, Medical Surgical $8.4B, Diabetes $2.8B. Total FY2025 revenue: $33.5B. Percentages rounded.

Leadership

Geoff Martha

CEO since 2020. Chairman and CEO since April 2020, Martha joined Medtronic in 2011 after nearly two decades at GE Healthcare and GE Capital. He restructured Medtronic into 20 operating units to accelerate decision-making and has driven the company's pivot from a device manufacturer toward a healthcare technology platform company. A Penn State Smeal College of Business graduate, Martha championed the AiBLE ecosystem, the Hugo robotics program, the PFA portfolio buildout, and the pending MiniMed spinoff.

Thierry Piéton, EVP and Chief Financial Officer: Joined March 2025 from Renault Group, where he delivered record operating margins and free cash flow. Hired specifically to drive margin expansion and execute the MiniMed IPO/split-off.

Michael Carter, SVP and President, Cranial & Spinal Technologies: Leads the $5B+ spine and cranial franchise including the AiBLE ecosystem and the newly FDA-cleared Stealth AXiS surgical robotics platform. The spine unit is the backbone of Medtronic's navigation and robotics strategy.

Que Dallara, EVP and President, Medtronic Diabetes (CEO-designate, MiniMed): Leading the diabetes unit through its spinoff as MiniMed. Under her leadership, Diabetes delivered six consecutive quarters of double-digit growth and launched the Simplera Sync CGM and Instinct sensor partnership with Abbott.

Jason Weidman, SVP and President, Coronary & Renal Denervation: Driving the $585M CathWorks acquisition and the Symplicity Spyral renal denervation program. The CathWorks FFRangio system adds AI-powered coronary physiology assessment to the cardiovascular portfolio.

The AI Angle

AI embedded in devices, not chatbots

Medtronic's AI strategy is fundamentally different from most tech companies: it deploys narrow, clinically validated AI models directly into physical devices operating at the point of care. The flagship examples are the AiBLE ecosystem for spine surgery (which now includes the Stealth AXiS platform with LiveAlign real-time segmental tracking), the GI Genius intelligent endoscopy module that uses deep learning to detect polyps missed by human clinicians at a 26% rate, and the MiniMed 780G's Meal Detection Technology algorithm that auto-corrects insulin delivery. The company has also built AccuRhythm AI into the LINQ insertable cardiac monitor to improve atrial fibrillation detection, and Touch Surgery Enterprise uses AI to automatically segment and annotate surgical videos for post-operative review. On the infrastructure side, Medtronic partners with NVIDIA, integrating IGX industrial-grade edge AI hardware and the Holoscan real-time AI computing platform into the GI Genius module. The company acquired Digital Surgery (London) in 2020, which provided the core surgical video AI and algorithm development team that now powers both the Hugo robotics platform and Touch Surgery Enterprise. Medtronic is investing up to $200M to co-develop the next-generation GI Genius AI Access platform with Cosmo Pharmaceuticals. The pending CathWorks acquisition ($585M) adds another AI-native product — the FFRangio system uses AI and computational science to map the entire coronary tree from standard angiograms, eliminating invasive pressure wires. Medtronic established a centralized AI Center of Excellence to unify data assets, regulatory expertise, and algorithm development across business units. Chief Technology and Innovation Officer Ken Washington, who joined from Ford in 2023 and led the AI-robotics convergence strategy, retired in November 2025. His digital technology group in London continues designing AI features for surgical robotics. The company's UNiD Adaptive Spine Intelligence platform — with over 40,000 patient cases — represents the largest surgical planning database for spine surgery and feeds predictive models for patient-specific implant design. The competitive positioning is strong but narrowly scoped. Unlike Intuitive Surgical (which dominates soft tissue robotics) or GE HealthCare (imaging AI), Medtronic's AI moat is built on closed-loop device ecosystems where proprietary clinical data feeds models that improve device performance. The risk is execution speed: regulatory timelines for AI-enabled medical devices remain long, and competitors like Johnson & Johnson (Ottava robotics) and Stryker (Mako) are investing aggressively in their own AI-surgical platforms.

Financial Snapshot

Revenue (TTM): $34.8B — TTM ending October 31, 2025 | Net Income: $4.8B net income (TTM)

Margins: Gross 65.6%, operating ~17.8% (FY2025), net 13.7%

Medtronic is a Dividend Aristocrat with 48 consecutive years of increases, yielding ~2.8% at current prices with a 76.5% payout ratio. FY2025 operating profit grew 16% to $5.95B, and the company raised FY2026 non-GAAP EPS guidance after Q1. Free cash flow increased 25% in Q1 FY2026. The upcoming MiniMed spinoff should be immediately accretive to gross margin (~50bps) and operating margin (~100bps). Capital allocation is balanced between the $2.84/share annual dividend, modest buybacks reducing the share count incrementally each quarter, and targeted M&A like the $585M CathWorks deal.

1-Year Performance

MDT trades at $100.88, approximately 5% below its 52-week high of $106.33 (hit November 26, 2025) and 27% above the 52-week low of $79.55 (April 9, 2025). TTM total return is approximately 19%.

Medtronic's stock reversed a multi-year underperformance trend in 2025, forming a Golden Crossover following strong FQ2 2026 earnings. The 71% surge in Cardiac Ablation Solutions revenue from PFA products was the primary catalyst, alongside Elliott Management's activist engagement which prompted two new board seats and new growth/operating committees. The stock has also benefited from the raised FY2026 EPS guidance and positive CMS renal denervation coverage developments. Tariff headwinds (~$185M expected FY2026 impact) and the $382M antitrust verdict in Applied Medical's favor remain near-term overhangs.

Recent News

Fun Fact: Medtronic's AiBLE spine surgery ecosystem includes UNiD Adaptive Spine Intelligence, which holds over 40,000 patient cases — the world's largest surgical planning database for spine procedures. Surgeons use it to generate AI-driven predictive models for custom-engineered spinal rods, where the algorithm models the patient's specific spinal curvature and predicts post-operative alignment. More than 1,000 cases per month in the U.S. alone run through this AI planning pipeline. The company's original spine navigation system, StealthStation, traces its lineage back to technology adapted from military GPS guidance systems in the 1990s.